Short-term glucagon stimulation test of C-peptide effect on glucose utilization in patients with type 1 diabetes mellitus

2015 ◽  
Vol 53 (12) ◽  
pp. 1361-1369 ◽  
Author(s):  
Viliam Mojto ◽  
Zuzana Rausova ◽  
Jana Chrenova ◽  
Ladislav Dedik
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Glucose Utilization ◽  
Stimulation Test ◽  
Glucagon Stimulation Test ◽  
Short Term ◽  
C Peptide

Anti-inflammatory effects of C-peptide on kidney of type 1 diabetes mellitus animal model

2019 ◽  
Vol 47 (1) ◽  
pp. 721-726 ◽  
Author(s):  
Michelle T. Alves ◽  
Amanda C. S. Chaves ◽  
Ana Paula M. Almeida ◽  
Ana Cristina Simões e Silva ◽  
Stanley de A. Araújo ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Animal Model ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
C Peptide ◽  
Anti Inflammatory

scholarly journals Comparison of proinsulin and C-peptide secretion in healthy versus long-standing type 1 diabetes mellitus cohorts: A pilot study

PLoS ONE ◽  
2018 ◽  
Vol 13 (11) ◽  
pp. e0207065 ◽  
Author(s):  
Catherine A. Sullivan ◽  
Jose M. Cacicedo ◽  
Iniya Rajendran ◽  
Devin W. Steenkamp
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Pilot Study ◽  
Type 1 Diabetes Mellitus ◽  
C Peptide ◽  
Peptide Secretion

scholarly journals Preserved C-peptide levels in overweight or obese compared with underweight children upon diagnosis of type 1 diabetes mellitus

2015 ◽  
Vol 20 (2) ◽  
pp. 92 ◽  
Author(s):  
Hyeoh Won Yu ◽  
Yun Jeong Lee ◽  
Won Im Cho ◽  
Young Ah Lee ◽  
Choong Ho Shin ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
C Peptide

scholarly journals Four-year clinical remission of type 1 diabetes mellitus in two patients treated with sitagliptin and vitamin D3

2016 ◽  
Vol 2016 ◽  
Author(s):  
Marcelo Maia Pinheiro ◽  
Felipe Moura Maia Pinheiro ◽  
Margareth Afonso Torres
Keyword(s):  
Diabetes Mellitus ◽  
Immune Response ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Vitamin D3 ◽  
Clinical Remission ◽  
Insulin Production ◽  
C Peptide ◽  
New Onset

Summary Type 1 diabetes mellitus (T1DM) is a chronic disease characterized by autoimmune destruction of pancreatic beta cells and inadequate insulin production. Remission criteria in T1DM take into account serum levels of C-peptide and glycosylated hemoglobin, as well as the dose of insulin administered to the patient. However, remission of T1DM lasting longer than 1 year is rare. We describe here the cases of two young women who presented with positive glutamic acid decarboxylase (GAD) antibody and classic clinical manifestations of T1DM. Both patients had a prior history of Hashimoto’s thyroiditis. They were initially treated with a basal-bolus regimen of insulin (glargine and lispro/glulisine). Once their blood glucose levels were controlled, they were started on oral sitagliptin 100 mg and vitamin D3 5000 IU daily. After this therapy, both patients achieved clinical diabetes remission for 4 years, along with a decrease in anti-GAD antibody levels. These benefits were probably associated with immunological effects of these medications. Inhibition of dipeptidyl peptidase 4 (DPP-4) in animal models deregulates Th1 immune response, increases secretion of Th2 cytokines, activates CD4+CD25+FoxP3+ regulatory T-cells and prevents IL-17 production. Vitamin D3 also activates CD4+CD25+FoxP3+ regulatory T-cells, and these medications combined can improve the immune response in patients with new-onset T1DM and probably promote sustained clinical remission. Learning points: The use of sitagliptin and vitamin D3 in patients with new-onset type 1 diabetes mellitus (T1DM) may help decrease the daily insulin requirement by delaying beta cell loss and improving endogenous insulin production. The use of sitagliptin and vitamin D3 in new-onset T1DM could help regulate the imbalance between Th17 and Treg cells. Age 14 years or above, absence of ketoacidosis and positive C-peptide levels in patients with T1DM are good criteria to predict prolonged T1DM remission. The determination of anti-GAD antibodies and C-peptide levels could be helpful in the follow-up of patients in use of sitagliptin and vitamin D3, which could be associated with prolonged T1DM clinical remission.

Short term pirenzepine treatment is ineffective in suppressing 24-h growth hormone secretion in type 1 diabetes mellitus

1993 ◽  
Vol 19 (3) ◽  
pp. 211-216 ◽  
Author(s):  
J. Krassowski ◽  
P. Szulc ◽  
A. Makowska ◽  
M. Godziejewska ◽  
W. Jeske ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Growth Hormone ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Hormone Secretion ◽  
Growth Hormone Secretion ◽  
Short Term

Impaired short-term blood pressure regulation and autonomic dysbalance in children with type 1 diabetes mellitus

Diabetologia ◽  
2007 ◽  
Vol 50 (12) ◽  
pp. 2417-2423 ◽  
Author(s):  
R. Dalla Pozza ◽  
S. Bechtold ◽  
W. Bonfig ◽  
S. Putzker ◽  
R. Kozlik-Feldmann ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Blood Pressure ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Blood Pressure Regulation ◽  
Pressure Regulation ◽  
Short Term

Short-term heart rate complexity is reduced in patients with type 1 diabetes mellitus

2008 ◽  
Vol 119 (5) ◽  
pp. 1071-1081 ◽  
Author(s):  
Michal Javorka ◽  
Zuzana Trunkvalterova ◽  
Ingrid Tonhajzerova ◽  
Jana Javorkova ◽  
Kamil Javorka ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Heart Rate ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Short Term ◽  
Heart Rate Complexity
Sign in / Sign up

Export Citation Format

Share Document